✦ LIBER ✦

9148 Phase 1 study of the toll-like receptor 9 (TLR9) agonist, IMO-2055, combined with erlotinib (E) and bevacizumab (B) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC)

✍ Scribed by Smith, D.A.; Conkling, P.; Richards, D.; Alemany, C.; Boyd, T.; Garbo, L.; Wu, H.; Wages, D.; Bexon, A.; Murphy, J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1b study results of IMO-2055, a no

✍ Smith, David A.; Conkling, Paul; Richards, Donald A.; Flores, Maria Regina C.; N 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Antitumor activity and safety of combina

✍ Smith, David A.; Conkling, Paul; Richards, Donald A.; Nemunaitis, John J.; Boyd, 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 287 KB

9003 ORAL Biomarker Analysis in BO21015,

✍ Mok, T.; Gorbunova, V.; Juhasz, E.; Szima, B.; Burdaeva, O.; Yu, C.J.; Delmar, P 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB